Catalyst Wire Dossier Catalyst Wire Dossier

Humacyte Human Acellular Vessel (HAV)

human acellular vessel · Humacyte, Inc.
Drug timelines are a Plus or Pro feature.

2 regulatory and trial events tracked for Humacyte Human Acellular Vessel (HAV), covering 2023-11-02 to 2024-11-25. Get the full timeline:

Most recent: Clinical Trial Update: An Observational Study to Evaluate the Safety and Efficacy of Humacyte's HAV for Arterial Replacement or Reconstruction in Ukrainian Patients With Life or Limb-threatening Vascular Trauma

See pricing